Topotecan and Melphalan for Retinoblastoma

Choice of Topotecan or Melphalan in Retinoblastoma Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04799002

Enrollment

Registered

2021-03-16

Start date

2021-03-11

Completion date

2027-12-30

Last updated

2021-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy Effect, Retinoblastoma

Keywords

Retinoblastoma, topotecan, Melphalan

Brief summary

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

Detailed description

To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.

Interventions

DRUGTopotecan

Topotecan intraocular injection for chemotherapy in retinoblastoma

DRUGMelphalan

Melphalan intraocular injection for chemotherapy in retinoblastoma

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* diagnosed as retinoblastoma * receiving eyeball-sparing treatment

Exclusion criteria

* disease progression during follow-up

Design outcomes

Primary

Measure	Time frame	Description
Eyeball-sparing rate	5 years after chemotherapy	Eyeball-sparing rate during chemotherapy in retinoblastoma patients

Secondary

Measure	Time frame	Description
Side effects	5 years after chemotherapy	Side effects during and after chemotherapy in retinoblastoma patients

Countries

China

Contacts

Primary ContactHuasheng Yang

yanghs64@126.com+00862087331539

Backup ContactHuijing Ye

yehuijing@qq.com+00862087331539

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026